CDCP1 and cancer: To assess whether antibody-induced loss of CDCP1 expression is a general phenomenon, we also examined the effect of these antibody treatments by western blotting lysates from 14 other cell lines from six different cancers (kidney, prostate, lung, colorectal, pancreatic, ovarian) that express only full-length CDCP1-FL (A498, 786-O, A549, HT29), a mixture of CDCP1-FL and CDCP1-CTF (DU145, EBC-1, HCT116, CAOV3, H1650, H1975, OVCAR420, TKCC23, TKCC2.1), or only CDCP1-CTF (TKCC05).